Vaya Knowledge Hub · India

Semaglutide in India: what patients should know

A plain-language guide to the semaglutide molecule, how it differs from a brand name, why medical assessment matters and what to discuss with a doctor.

Key point: Semaglutide is a prescription medicine in the GLP-1 receptor agonist family. “Semaglutide” is the molecule, while names such as Ozempic refer to specific branded products. The appropriate product, indication and dose depend on an individual clinical assessment.

What is semaglutide?

Semaglutide acts on the GLP-1 pathway, which is involved in appetite, digestion and glucose regulation. Depending on the specific product and approved indication, semaglutide may be used in diabetes care or chronic weight management. It should not be treated as a general-purpose slimming product.

Is semaglutide the same as Ozempic?

No. Semaglutide is an active pharmaceutical ingredient. Ozempic is one brand containing semaglutide. A brand name also carries a particular formulation, strength, delivery system and approved indication. This distinction is important when comparing products or reading information online.

Why has semaglutide become associated with weight loss?

Large clinical trials have studied semaglutide for chronic weight management. In the STEP 1 trial, adults with overweight or obesity receiving semaglutide 2.4 mg plus lifestyle intervention achieved greater average weight reduction than participants receiving placebo plus lifestyle intervention. Individual results vary and trial outcomes do not guarantee a particular result.

How is suitability assessed?

A doctor considers more than a number on a scale. Assessment can include BMI, weight-related conditions, medical history, current medicines, previous weight-management efforts, gastrointestinal history and other risk factors. The approved indication of the specific product must also be considered.

At Vaya, this assessment is intended to happen through a doctor conversation rather than an automated eligibility quiz. A website can explain the process and collect contact details, but it cannot replace clinical judgement.

What should patients know about dosing?

Semaglutide products can use staged dose escalation. Dosing instructions vary by product and indication. Patients should use only the dose prescribed and follow the product information. Questions about missed doses, dose increases, side effects or restarting after an interruption should be directed to a clinician.

Common side effects

Frequently reported effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. Some people experience few symptoms; others may find gastrointestinal effects difficult. Product information contains important warnings and contraindications. Severe or persistent symptoms require medical attention.

How much does treatment cost in India?

Total cost can have several components: clinical support, the prescribed medicine, the dose required and pharmacy charges. Prices and product availability can change. Vaya's base membership starts from ₹699 per month and medication is separate if prescribed. Patients should ask for the current medicine price rather than relying on an old online price.

Frequently asked questions

Can semaglutide be used by anyone who wants to lose weight?

No. It is a prescription medicine with specific indications, precautions and risks. Suitability is a clinical decision.

Is a generic product automatically equivalent to a branded product?

Do not assume equivalence based on the molecule name alone. Product approval, formulation, strength, delivery device, indication and dispensing source matter.

Do I still need to change diet and activity?

Medical weight management is generally considered alongside nutrition, physical activity and other behavioural factors. A clinician can help tailor these recommendations.

What happens if I stop?

Weight regain can occur after discontinuing weight-management medication. A maintenance or discontinuation plan should be discussed with the treating clinician.

References

  1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002.
  2. Rubino D et al. Continued Weekly Subcutaneous Semaglutide and Weight Loss Maintenance. JAMA. 2021.
  3. Central Drugs Standard Control Organisation, Subject Expert Committee recommendations, Endocrinology & Metabolism, 8 April 2026.

Related guides